Medicare Enrolled
Dr. Adarsh Sidda, M.D.
Hematology & Oncology · Denison, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Sidda from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Sidda? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Sidda
Dr. Adarsh Sidda is a hematology & oncology in Denison, TX, with 10 years in practice. Based on federal Medicare data, Dr. Sidda performed 116,467 Medicare services across 3,874 unique beneficiaries.
Between the years covered by Open Payments, Dr. Sidda received a total of $1,817 from 25 pharmaceutical and/or device companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Sidda is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 10 years in practice▲ Top 5% volume in TX$ $1,817 industry payments
Medicare Practice Summary
Medicare Utilization ↗116,467
Medicare services
Top 5% in TX for hematology & oncology
3,874
Unique beneficiaries
$13
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~11,647 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 29,580 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 17,700 | $43 | $137 |
| Oxaliplatin chemotherapy injection | 10,550 | $0 | $33 |
| Paclitaxel chemotherapy injection | 8,847 | $0 | $8 |
| Nivolumab injection (Opdivo) | 8,800 | $24 | $76 |
| Iron sucrose injection (Venofer) | 7,600 | $0 | $2 |
| Contrast dye for imaging (iodine-based) | 6,340 | $0 | $3 |
| Darbepoetin injection (Aranesp) for anemia | 6,330 | $2 | $20 |
| Anti-nausea injection (fosaprepitant) | 3,750 | $0 | $5 |
| Denosumab injection (Prolia/Xgeva) | 3,660 | $19 | $66 |
| Dexamethasone injection (steroid) | 2,129 | $0 | $1 |
| Complete blood count (CBC) with differential | 965 | $8 | $36 |
| Comprehensive metabolic blood panel | 882 | $10 | $64 |
| Blood draw (venipuncture) | 852 | $8 | $20 |
| Injection, granisetron hydrochloride, 100 mcg | 790 | $0 | $24 |
| Injection, leucovorin calcium, per 50 mg | 537 | $3 | $25 |
| Anti-nausea injection (Aloxi/palonosetron) | 460 | $1 | $114 |
| Injection, fluorouracil, 500 mg | 407 | $2 | $13 |
| Administration of chemotherapy into vein, 1 hour or less | 386 | $97 | $707 |
| Office visit, established patient (30-39 min) | 341 | $94 | $368 |
| Injection, carboplatin, 50 mg | 333 | $2 | $300 |
| Office visit, established patient (20-29 min) | 286 | $62 | $250 |
| Injection of additional new drug or substance into vein | 278 | $12 | $108 |
| Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg | 274 | $3 | $373 |
| Lactate dehydrogenase (enzyme) level | 216 | $6 | $31 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 212 | $22 | $157 |
| Injection, cisplatin, powder or solution, 10 mg | 204 | $2 | $94 |
| Ferritin level test (iron stores) | 194 | $13 | $60 |
| Iron level test | 191 | $6 | $27 |
| Iron binding capacity test | 191 | $8 | $35 |
| Office visit, established patient, complex (40-54 min) | 185 | $132 | $496 |
| Injection, zoledronic acid, 1 mg | 178 | $6 | $431 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 157 | $45 | $313 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 138 | $54 | $211 |
| Injection, magnesium sulfate, per 500 mg | 134 | $1 | $6 |
| Irrigation of implanted venous access drug delivery device | 129 | $18 | $114 |
| Drug injection, under skin or into muscle | 124 | $10 | $96 |
| Administration of additional new drug or substance into vein, 1 hour or less | 116 | $48 | $344 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 116 | $131 | $3,675 |
| Administration of chemotherapy into vein, each additional hour | 109 | $21 | $161 |
| Injection, diphenhydramine hcl, up to 50 mg | 96 | $1 | $7 |
| Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session | 94 | $272 | $2,762 |
| Injection, fosnetupitant 235 mg and palonosetron 0.25 mg | 90 | $343 | $1,722 |
| PSA test (prostate cancer screening) | 77 | $18 | $94 |
| Ct scan of chest with contrast | 72 | $55 | $821 |
| Magnesium level test | 70 | $7 | $29 |
| Uric acid level test | 70 | $4 | $25 |
| Carcinoembryonic antigen (cea) protein level | 66 | $19 | $99 |
| Hospital follow-up visit, moderate complexity | 64 | $58 | $247 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 62 | $24 | $145 |
| Initial hospital admission, moderate complexity | 61 | $97 | $470 |
| New patient office visit (45-59 min) | 58 | $122 | $565 |
| New patient office visit, complex (60-74 min) | 58 | $161 | $709 |
| Infusion, normal saline solution , 1000 cc | 58 | $2 | $19 |
| Unclassified drugs | 56 | $1 | $8 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 54 | $1,109 | $4,802 |
| Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion | 54 | $15 | $94 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 54 | $90 | $657 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 52 | $73 | $70 |
| Administration of additional new drug or substance into vein using push technique | 51 | $42 | $289 |
| CT scan of abdomen and pelvis with contrast | 50 | $173 | $1,067 |
| Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | 43 | $122 | $500 |
| Microscopic examination for white blood cells with manual cell count | 38 | $4 | $22 |
| Complete blood count (CBC), automated | 38 | $6 | $34 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 19-9 | 33 | $20 | $128 |
| Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 | 30 | $20 | $128 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 30 | $15 | $100 |
| Phosphate level test | 28 | $5 | $24 |
| Hospital follow-up visit, high complexity | 28 | $91 | $357 |
| Blood creatinine level | 24 | $5 | $31 |
| Red blood count automated, with additional calculations | 20 | $5 | $26 |
| Initial hospital admission, high complexity | 20 | $133 | $694 |
| Infusion into a vein for hydration, 31-60 minutes | 18 | $19 | $256 |
| Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev | 18 | $178 | $700 |
| Infusion into a vein for hydration, each additional hour | 17 | $8 | $75 |
| Ct scan of soft tissue of neck with contrast | 16 | $64 | $658 |
| Telephone medical discussion with physician, 11-20 minutes | 16 | $69 | $231 |
| Injection of drug or substance into vein | 12 | $26 | $247 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
25.9% high complexity
69.1% medium
5.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$1,817
Total received (2018-2024)
Avg $454/year across 4 years
Bottom 38% in TX for hematology & oncology
25
Companies
54
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$937 (51.6%)
Other
Charitable contributions, space rental, and other categories
$863 (47.5%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$16 (0.9%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$1,235
2023$481
2022$86
2018$15
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$916
Incyte Corporation
$136
Inari Medical, Inc.
$66
PFIZER INC.
$52
Tempus AI, Inc
$43
Exelixis Inc.
$43
E.R. Squibb & Sons, L.L.C.
$42
Merck Sharp & Dohme LLC
$42
AstraZeneca Pharmaceuticals LP
$40
ABBVIE INC.
$39
Amgen Inc.
$38
GENZYME CORPORATION
$37
Medtronic, Inc.
$32
Takeda Pharmaceuticals U.S.A., Inc.
$32
ADC Therapeutics America, Inc.
$29
PharmaEssentia USA Corporation
$29
Daiichi Sankyo Inc.
$28
G1 Therapeutics, Inc.
$25
SOBI, INC
$24
Ipsen Biopharmaceuticals, Inc
$24
Astellas Pharma US Inc
$24
CTI BioPharma Corp.
$24
Aveo Pharmaceuticals, Inc.
$19
Stemline Therapeutics Inc.
$15
Bayer Healthcare Pharmaceuticals Inc.
$15
Top 3 companies account for 61.5% of total payments
Associated products mentioned in payments ›
BESREMI · CABOMETYX · CALQUENCE · COSELA · Doptelet · EPKINLY · Enhertu · FLOWTRIEVER CATHETER · FOTIVDA · FRUZAQLA · IMBRUVICA · IMFINZI · INLYTA · JAKAFI · KEYTRUDA · KISQALI · LUMAKRAS · NINLARO · Nubeqa · OPDIVO · OSTEOCOOL RF ABLATION SYSTEM · Onivyde · Orserdu · PADCEV · PEMAZYRE · PLUVICTO · S · SARCLISA · SCEMBLIX · TASIGNA · Vonjo · Xospata
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (52%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $2 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
3
Per 100K population
2.1
County median income
$70,455
Nearest hospital
TEXOMA MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Sidda is a mixed practice specialist, with above-average Medicare volume (top 5% in TX), and low-engagement industry engagement.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Sidda experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Sidda performed 29,580 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Sidda receive payments from pharmaceutical companies?
Yes. Dr. Sidda received a total of $1,817 from 25 companies across 54 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Sidda's costs compare to other hematology & oncologys in Denison?
Dr. Sidda's average Medicare payment per service is $13. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Sidda) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Denison
Browse hematology & oncologys in Denison ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Incyte Corporation Payments to Doctors
See all physicians who received payments from Incyte Corporation.
By company
Inari Medical, Inc. Payments to Doctors
See all physicians who received payments from Inari Medical, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology